NCT01745133View on ClinicalTrials.gov

Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis

PHASE4CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

August 31, 2014

Conditions
Psoriasis
Interventions
DRUG

vehicle foam

clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks

DRUG

calcipotriene

clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks

DRUG

calcipotriene + clobetasol propionate

clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks

Trial Locations (1)

40217

DermResearch, PLLC, Louisville

All Listed Sponsors
collaborator

Stiefel, a GSK Company

INDUSTRY

lead

Leon Kircik, M.D.

OTHER

NCT01745133 - Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis | Biotech Hunter | Biotech Hunter